Lancet Respiratory Medicine

Papers
(The H4-Index of Lancet Respiratory Medicine is 90. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Postoperative CPAP after major abdominal surgery872
Time to move away from an oxygen-centric model of pulmonary infarction?571
Concerns regarding a suggested long COVID paradigm – Authors' reply489
European Respiratory Society International Congress 2022456
Video laryngoscopy is not the nemesis of direct laryngoscopy409
Major gaps in childhood pneumonia research priorities remain325
The course of action for effective anti-cytokine treatment in COVID-19312
Correction to Lancet Respir Med 2024; 12: 129–40295
Correction to Lancet Respir Med 2019; 7: 745–56291
Rituximab for connective tissue disease-associated interstitial lung disease277
Savolitinib in NSCLC: progress in the MET exon 14 journey242
Broad protection from SARS-CoV-2 variants without antigen matching232
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?222
Australia bans engineered stone to prevent silicosis220
The burden of tuberculosis in Libya216
Thoracentesis: an old story and some new sources196
Eat or heat: fuel poverty and childhood respiratory health185
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership178
Interstitial lung disease: a decade of progress and hope178
Predicted bodyweight—a misleading metric for tidal volume titration?177
Opioids bring peace to patients with IPF cough173
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress170
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials169
Impact of Myanmar's earthquake on respiratory health165
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis161
Chronic obstructive pulmonary disease: 10 years of precision-guided success158
US Senate committee investigates asthma inhaler prices157
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros157
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop155
Predatory publishers appear in PubMed (and your inbox)154
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis152
Advancing precision medicine for acute respiratory distress syndrome152
GOLD report: 2022 update149
Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement147
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial145
FLiRTing with danger as SARS-CoV-2 variants evolve145
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study145
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study145
Long COVID: systemic inflammation and obesity as therapeutic targets143
Concerns about PRISm141
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply138
Priorities for NICE in health and social care138
Genetic associations and lung function in IPF: unexpected answers, persistent questions138
Claudio Castanos—leader in cystic fibrosis care in Argentina138
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials131
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts131
Solid and semi-solid perspectives in thoracic surgery131
US EPA signals renewed regulatory scrutiny of toxic air pollution131
Correction to Lancet Respir Med 2025; 13: 244–55131
Association of SARS-CoV-2 infection and persistence with long COVID130
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study128
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial127
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO125
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial124
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts123
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials122
Correction to Lancet Respir Med 2022; 10: 972–84121
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis120
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta119
Vaccination in the world's top athletes119
Awake prone positioning in COVID-19: is tummy time ready for prime time?118
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges118
Extracorporeal cardiopulmonary resuscitation: not why, but how117
Trump administration decimates worker health oversight113
Correction to Lancet Respir Med 2021; 9: 1275–87112
Chronic cough as a disease: implications for practice, research, and health care111
Improving lifelong respiratory health after preterm birth111
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial110
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study110
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis109
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub108
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial107
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis107
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co106
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s106
Nintedanib for treating progressive fibrosing interstitial lung diseases105
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial104
Venus and Mars: chest wall deformity and thoracic disease104
Trouble with promoting lung cancer screening in never-smokers104
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO103
COPD: a complex, multifactorial, but preventable disease?101
Underappreciated causes of obstructive lung disease97
Correction to Lancet Respir Med 2023; 11: 1064–7495
Spirometry in female individuals – Authors' reply95
Health effects from climate-driven events: lessons learnt93
Unveiling a hidden phenotype of early tuberculosis92
Prevalence of sleep-disordered breathing in an African general population: The Benin Society and Sleep (BeSAS) study92
COP27 Climate Change Conference: urgent action needed for Africa and the world91
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial91
Developments and priorities in bronchiectasis research91
Liberal or restrictive transfusion for VV ECMO90
0.10863709449768